| Literature DB >> 32714405 |
Changlin Zhang1,2, Yingdi Liao1,2, Lingling Liu1,2, Yifan Sun1,2, Shaoqin Lin1,2, Jiaying Lan1,2, Hui Mao1,2, Haoxuan Chen1,2, Yuanqi Zhao1,2,3,4.
Abstract
OBJECTIVES: This study aims to study the material basis and effective mechanism of musk for ischemic stroke (IS) based on the network pharmacology approach.Entities:
Year: 2020 PMID: 32714405 PMCID: PMC7354650 DOI: 10.1155/2020/4063180
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1A time table about the use of all databases.
Figure 2A flow chart of the technical strategy used in this study.
Active chemical constituents of musk.
| No | Compound name | Molecular formula | Molecular weight (g/mol) | CID |
|---|---|---|---|---|
| 1 | 17-Beta-estradiol | C18H24O2 | 272.4 | 5757 |
| 2 | 2, 6-Decamethylene pyridine | C15H23N | 217.4 | 5316410 |
| 3 | 3, 5-Dihydroxybenzoic acid | C7H6O4 | 154.1 | 7424 |
| 4 | 3-Alpha-hydroxy-5alpha-androstan-17-one | C19H30O2 | 290.4 | 5879 |
| 5 | 3-Beta-hydroxy-5alpha-androstan-17-one | C19H30O2 | 290.4 | 441302 |
| 6 | 3-Methylcyclotridecan-1-one | C14H26O | 210.4 | 3017257 |
| 7 | 5-cis-Cyclopentadecen-1-one | C15H26O | 222.4 | 5316264 |
| 8 | 5-cis-Cyclotetradecen-1-one | C14H24O | 208.4 | 5316269 |
| 9 | Allantoin | C4H6N4O3 | 158.1 | 204 |
| 10 | Alpha-estradiol | C18H24O2 | 272.4 | 6432565 |
| 11 | Androst-4-ene-3, 17-dione | C19H26O2 | 286.4 | 6128 |
| 12 | Androsterone | C19H30O2 | 290.4 | 5879 |
| 13 | Cholesterol | C27H46O | 386.7 | 5997 |
| 14 | Cholesteryl ferulate | C37H54O4 | 562.8 | 22375086 |
| 15 | Cyclotetradecan-1-one | C14H26O | 210.4 | 77153 |
| 16 | Cyclovirobuxine | C26H46N2O | 402.7 | 260439 |
| 17 | Decamine | C30H40Cl2N4 | 527.6 | 10649 |
| 18 | Estragole | C10H12O | 148.2 | 8815 |
| 19 | Hydroxymuscopyridine A | C16H25NO | 247.4 | 184938 |
| 20 | Hydroxymuscopyridine B | C16H25NO | 247.4 | 184939 |
| 21 | Morin | C4H6N4O3 | 302.2 | 5281670 |
| 22 | Musclide A1 | C8H18O5S | 226.3 | 5319969 |
| 23 | Muscol | C12H17NO | 191.3 | 4284 |
| 24 | Muscone | C16H30O | 238.4 | 10947 |
| 25 | Muscopyridine | C16H25N | 231.4 | 193306 |
| 26 | Musennin | C51H82O21 | 1031.2 | 441933 |
| 27 | N-Nonane | C9H20 | 128.3 | 8141 |
| 28 | Normuscone | C15H28O | 224.4 | 10409 |
| 29 | Testosterone | C19H28O2 | 288.4 | 6013 |
Figure 3The veen map of targets' intersection of musk and ischemic stroke.
Figure 4“Ingredient-target-pathway/disease network” of musk (the heptagon is on behalf of the musk compounds, the star node represents prediction target, the yellow circle represents the enrichment pathway, and the red and green squares represent the disease phenotype).
Figure 5The core target network of musk for ischemic stroke (color and size of nodes reflected degree centrality, while the edge thickness and color's depth reflected the combined score).
GO analysis was implemented on core targets.
| Category | Term | Count |
|
|---|---|---|---|
| GOTERM BP DIRECT | GO:0045944-positive regulation of transcription from RNA polymerase II promoter | 36 | 4.65 |
| GOTERM BP DIRECT | GO:0045893-positive regulation of transcription, DNA-templated | 28 | 2.78 |
| GOTERM BP DIRECT | GO:0007568-aging | 16 | 5.75 |
| GOTERM BP DIRECT | GO:0042493-response to drug | 19 | 1.64 |
| GOTERM BP DIRECT | GO:1902895-positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 9 | 4.48 |
| GOTERM BP DIRECT | GO:0010628-positive regulation of gene expression | 17 | 3.44 |
| GOTERM BP DIRECT | GO:0008217-regulation of blood pressure | 11 | 1.16 |
| GOTERM BP DIRECT | GO:0001666-response to hypoxia | 14 | 4.59 |
| GOTERM BP DIRECT | GO:0051091-positive regulation of sequence-specific DNA binding transcription factor activity | 12 | 6.31 |
| GOTERM BP DIRECT | GO:0043066-negative regulation of the apoptotic process | 19 | 1.53 |
| GOTERM MF DIRECT | GO:0008134-transcription factor binding | 19 | 4.57 |
| GOTERM MF DIRECT | GO:0019899-enzyme binding | 19 | 7.25 |
| GOTERM MF DIRECT | GO:0042802-identical protein binding | 24 | 2.39 |
| GOTERM MF DIRECT | GO:0005515-protein binding | 77 | 2.53 |
| GOTERM MF DIRECT | GO:0019901-protein kinase binding | 16 | 7.65 |
| GOTERM MF DIRECT | GO:0044212-transcription regulatory region DNA binding | 13 | 9.23 |
| GOTERM MF DIRECT | GO:0046982-protein heterodimerization activity | 16 | 1.36 |
| GOTERM MF DIRECT | GO:0003707-steroid hormone receptor activity | 8 | 1.43 |
| GOTERM MF DIRECT | GO:0005102-receptor binding | 14 | 2.98 |
| GOTERM MF DIRECT | GO:0000978-RNA polymerase II core promoter proximal region sequence-specific DNA binding | 14 | 3.18 |
| GOTERM CC DIRECT | GO:0005654-nucleoplasm | 39 | 2.19 |
| GOTERM CC DIRECT | GO:0005829-cytosol | 41 | 2.37 |
| GOTERM CC DIRECT | GO:0043234-protein complex | 15 | 8.82 |
| GOTERM CC DIRECT | GO:0005886-plasma membrane | 45 | 1.05 |
| GOTERM CC DIRECT | GO:0005615-extracellular space | 25 | 1.06 |
| GOTERM CC DIRECT | GO:0005576-extracellular region | 27 | 1.66 |
| GOTERM CC DIRECT | GO:0005901-caveola | 8 | 2.46 |
| GOTERM CC DIRECT | GO:0000790-nuclear chromatin | 11 | 2.77 |
| GOTERM CC DIRECT | GO:0043005-neuron projection | 11 | 1.91 |
| GOTERM CC DIRECT | GO:0005634-nucleus | 46 | 1.36 |
KEGG enrichment analysis was performed on core targets.
| Category | Term | Count |
|
|---|---|---|---|
| KEGG PATHWAY | hsa04668: TNF signaling pathway | 18 | 3.55 |
| KEGG PATHWAY | hsa04915: estrogen signaling pathway | 17 | 1.87 |
| KEGG PATHWAY | hsa04917: prolactin signaling pathway | 14 | 1.23 |
| KEGG PATHWAY | hsa04722: neurotrophin signaling pathway | 16 | 6.49 |
| KEGG PATHWAY | hsa04660: T-cell receptor signaling pathway | 15 | 7.24 |
| KEGG PATHWAY | hsa04024: cAMP signaling pathway | 19 | 9.88 |
| KEGG PATHWAY | hsa04068: FoxO signaling pathway | 16 | 3.29 |
| KEGG PATHWAY | hsa04066: HIF-1 signaling pathway | 14 | 6.72 |
| KEGG PATHWAY | hsa04932: nonalcoholic fatty liver disease (NAFLD) | 15 | 2.01 |
| KEGG PATHWAY | hsa04015: Rap1 signaling pathway | 17 | 2.26 |
Figure 6Core network clustering diagram of musk for ischemic stroke.
Figure 7KEGG enrichment analysis of core PPI clusters.
Figure 8Multidimensional network of “core component-target-pathway.”